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Cancer Therapy: Clinical
Valproic Acid at Therapeutic Plasma Levels May Increase
5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes
Maria Teresa Voso,1 Valeria Santini,2 Carlo Finelli,3 Pellegrino Musto,4 Enrico Pogliani,5
Emanuele Angelucci,6 Giuseppe Fioritoni,7 Giuliana Alimena,8 Luca Maurillo,9
Agostino Cortelezzi,10 Francesco Buccisano,11 Marco Gobbi,12 Lorenza Borin,5 Anna Di Tucci,6
Gina Zini,1 Maria Concetta Petti,13 Giovanni Martinelli,3 Emiliano Fabiani,1 Paola Fazi,14
Marco Vignetti,14 Alfonso Piciocchi,14 Vincenzo Liso,15 Sergio Amadori,11 and Giuseppe Leone1
Abstract Purpose: Epigenetic changes play a role and cooperate with genetic alterations in the
pathogenesis of myelodysplastic syndromes (MDS). We conducted a phase II multi-
center study on the combination of the DNA-methyltransferase inhibitor 5-azacytidine
(5-AZA) and the histone deacetylase inhibitor valproic acid (VPA) in patients with higher
risk MDS.
Experimental Design:We enrolled 62 patients with MDS (refractory anemia with excess
blasts, 39 patients; refractory anemia with excess blasts in transformation, 19 patients;
and chronic myelomanocytic leukemia (CMML), 4 patients) and an International Prog-
nostic Scoring System (IPSS) rating of Intermediate-2 (42 patients) or high (20 patients).
VPA was given to reach a plasma concentration of >50 μg/mL, then 5-AZA was added
s.c. at 75 mg/m2 for 7 days in eight monthly cycles.
Results: The median overall survival was 14.4 months. At a median follow-up of
12 months (range, 0.7-21.0), the disease progressed in 20 patients, with 21% cumulative
incidence of progression. Of 26 patients who completed eight cycles, 30.7% obtained
complete or partial remission, 15.4% had a major hematologic improvement, whereas
38.5% showed stable disease. Drug-related toxicity was mild. Favorable prognostic
factors for survival were IPSS Intermediate-2 and plasma VPA of ≥50 μg/mL (log rank
= 0.013 and 0.007, respectively). Analysis of polymorphisms important for the metab-
olism of the drugs used in the trial showed that carriers of the CYP2C19*2 variant of
cytochrome P450 required higher VPA doses to achieve the target VPA plasma concen-
tration of 50 μg/mL on day 1 of 5-AZA treatment (P = 0.0021).
Conclusion: Our data show that the 5-AZA/VPA combination is active and safe in pa-
tients with MDS with a poor prognosis. Achievement of VPA therapeutic levels may
indeed increase 5-AZA efficacy.
Epigenetic transcriptional silencing of genes important for car-
cinogenesis, including cell cycle, apoptosis, DNA repair, and de-
toxification are likely to contribute to the leukemogenic event
underlying myelodysplastic syndromes (MDS) and acute mye-
loid leukemias (AML).
The transcriptional silencing of known or candidate tumor
suppressor genes depends not only on DNA methylation, but
also on additional epigenetic events such as bimethylation
and trimethylation of histone lysine residues and recruitment
of methylated DNA-binding proteins (1). Methyl CpG-binding
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proteins are also often part of large corepressor complexes
which recruit histone deacetylases (HDAC) and histone-methyl
transferase on target promoter sequences (2, 3).
Several tumor suppressor genes have been shown to be hy-
permethylated in MDS and the frequency of methylation has
been associated with unfavorable prognosis (4, 5). The poten-
tial reversibility of DNA and chromatin modifications favored
the development of two classes of epigenetic drugs which inhib-
it enzymatic activities involved in epigenetic silencing, DNA
methyltransferase (DNMT) and HDAC, respectively. Among
DNMT inhibitors (DNMTi), azacytidine (5-azacytidine; Vidaza,
Celgene, Corp.), and decitabine (5-aza-2′-deoxycytidine; Daco-
gen, MGI Pharma, Inc.) are available in the clinical setting and
have been approved for the treatment of MDS. Both agents are
incorporated after cellular uptake into newly synthesized RNA
and DNA, respectively. Then, the 5-azacytosine rings covalently
bind DNMT1 and the resulting adducts are excised from the
DNA, ubiquitinated and targeted to the proteosome for degra-
dation (6). This induces loss of methylation in one of the DNA
daughter molecules, blocks DNA synthesis, and elicits the re-
expression of silenced genes. Azacytidine also induces RNA deg-
radation and inhibition of protein synthesis. The multiple
effects on DNA, RNA, and proteins, like the mere formation
of DNA/DNMTi adducts, also account for the cytotoxicity ob-
served during treatment (7, 8).
HDAC inhibitors (HDACi) on the other hand, induce hyper-
acetylation of lysine residues in the histone tails, which contri-
butes to shifting the chromatin structure to a transcriptionally
active state (8). Additionally, a growing number of non-histone
proteins, like heat shock proteins, shuttle proteins, and tran-
scription factors, are acetylated by HDAC, inducing growth ar-
rest, differentiation, or apoptosis in vitro and in vivo (8). HDACi
have shown activity in MDS and AML in vivo and among them,
vorinostat (Zolinza; Merck) has been approved for recurrent
cutaneous T-cell lymphoma (9).
DNMTi and HDACi have been shown to synergize in vitro to
induce the expression of oncosuppressor genes and apoptosis
(10). Several phase I studies have investigated the activity of
this combination in vivo (11–13).
We conducted a multicenter phase II study on the combina-
tion of the DNMTi 5-azacytidine (5-AZA), the HDACi valproic
acid (VPA), and all-trans retinoic acid (ATRA) in patients with
intermediate-2/high-risk MDS, according to the International
Prognostic Scoring System (IPSS). We were interested in the
clinical activity of the DNMTi/HDACi combination and in the
pharmacogenetic profile associated with treatment response.
Similar to previous reports, the study also included patients
with refractory anemia with excess blasts (RAEB) in transforma-
tion (RAEBT) and CMML, in which azacytidine had been prov-
en effective (11–14). Because demethylating agents have been
shown to restore sensitivity to differentiation-inducing agents
(15), ATRA was added to unresponsive patients after four
5-AZA/VPA cycles.
Patients and Methods
Eligibility and treatment. The multicenter study GIMEMA
MDS0205 (EudraCT no. 2005-004811-31) included 62 patients from
17 Italian Hematology Centers. Patients' ages were 18 years or older,
with a diagnosis of RAEB or RAEBT according to the French-American-
British classification criteria, and an IPSS score of Intermediate-2 or
High (16). The protocol also included patients with a diagnosis of
chronic myelomonocytic leukemia according to the modified French-
American-British criteria, and a WBC count of ≤13 × 109/L. Bone mar-
row morphology was centrally reviewed before enrollment.
Table 1. Patient characteristics
n (%)
Sex
Male 43 (69.4)
Female 19 (30.6)
Age
Median (range) 69.6 (52.9-83.2)
Diagnosis
RAEB 39 (62.90)
RAEBT 19 (30.65)
CMML 4 (6.45)
MDS history
De novo 60 (97)
Therapy-related 2 (3)
IPSS score
Intermediate-2 42 (67.74)
High 20 (32.26)
Karyotype
Chromosome 7 8
Chromosome 5 3
Complex 11
Normal 15
Other 25
Bone marrow blasts (%)
Median (range) 16 (6.0-32.5)
Hemoglobin (g/dL)
Median (range) 9.0 (5.9-14.5)
Platelets (109/L)
Median (range) 54.0 (4.0-653.0)
WBC (109/L)
Median (range) 2.7 (0.7-34.0)
Translational Relevance
Epigenetic treatment has recently gained great in-
terest as a new and effective treatment option for pa-
tients with myelodysplastic syndrome. The role of
combination therapies remains to be defined. In this
article, we report the results of a phase II multicenter
study from the Italian Cooperative Group GIMEMA
on the combination of the DNA-methyltransferase in-
hibitor 5-azacytidine (5-AZA) and the histone deace-
tylase inhibitor valproic acid (VPA) in patients with
higher risk myelodysplastic syndrome. We show that
patients achieving VPA concentrations of ≥50 μg/mL
have a favorable outcome, indicating that the associ-
ation of VPA may indeed improve the response to
azacytidine. We also did pharmacogenetic analyses
demonstrating that carriers of the CYP2C19*2 allele,
an enzyme important for the metabolism of VPA, re-
quired higher VPA doses to achieve a VPA concen-
tration of >50 μg/mL. This underlines the necessity
to include pharmacogenetic analyses into future
trials on epigenetic treatment to define patient-
tailored approaches.
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Other inclusion criteria were an Eastern Cooperative Oncology
Group performance status score of 0 to 2, and adequate hepatic and
renal functions. The primary objective of the study was to assess efficacy
as complete remission (CR) or partial remission (PR) rates for the com-
bination of VPA and 5-AZA (Vidaza, Celgene) ± ATRA in the treatment
of MDS.
VPA was given orally on day 0 at 600 to 1,500 mg daily to reach a
final plasma concentration of >50 μg/mL, then 5-AZA was added s.c. at
a standard dose of 75 mg/m2 daily, 7 days for eight cycles, every 4
weeks. In case of minor response, stable disease or failure after four
cycles, ATRA was added at 30 mg/m2 orally daily, on days 8 to 27 for
four cycles. Treatment was continued in responding patients until
response persisted.
Patients were allowed to receive supportive care, including blood
transfusions, antibiotics, and antiemetics, as clinically indicated, but
not growth factors, except for granulocyte colony-stimulating factor in
case of life-threatening infections. The protocol had been approved by
the local ethical committees of the participating centers. All patients
signed informed consent in accordance with the Declaration of Helsinki,
following institutional guidelines.
Response criteria. Hematologic response was defined according to
the International Working Group Criteria for MDS (17). A CR
required the disappearance of all signs and symptoms related to the
disease, bone marrow blasts <5%, and peripheral blood absolute neu-
trophil count of ≥19/L, platelet count of ≥100 109/L or more, hemo-
globin ≥110 g/L, untransfused. PR included all CR criteria, except for
blast counts, which had to decrease to ≥50% of pretreatment values.
VPA levels were measured on day 0 of each course of therapy and
dosage was adapted accordingly to achieve the target concentration of
50 μg/mL.
Isolation of mononuclear cells and genotyping for enzymatic polymorph-
isms. Bone marrow mononuclear cells were separated using Ficoll-
Paque PLUS gradient centrifugation (Amersham Biosciences AB). Gen-
otyping of GSTP1-Ile105Val, CYP2C19*2, and CYP2C19*3 was done
by PCR-RFLP, as previously described (18). We designed a PCR-RFLP
technique to study polymorphisms of the cytidine deaminase promoter
region (CDA-897C>A and CDA-92A>G). The CDA-451C>T variant and
haplotypes for CDA-897, CDA-451, and CDA-92 were defined accord-
ing to Fitzgerald et al. (19). The CYP3A4-A290G polymorphic variant
was studied by a mismatch PCR-RFLP technique, as previously described
(20). Oligonucleotide sequences and PCR-RFLP conditions are detailed
in Supplementary Table S1.
Statistical analysis. Differences in the distributions of prognostic
factors in subgroups were analyzed by χ2 test and the Wilcoxon or
Kruskal-Wallis test for categorical and continuous covariates, respective-
ly. A nonparametric test (Friedman test) was used to compare observa-
tions repeated on the same subject. Median follow-up time was
estimated by reversing the codes for the censoring indicator in a
Kaplan-Meier analysis. Survival was defined as the time from registration
to death or date of the last follow-up. Differences in survival were calcu-
lated by the log rank test in univariate analysis and by the Cox regression
model in multivariable analysis. The probability of cumulative inci-
dence of disease progression or transformation to AML was estimated
using the appropriate nonparametric method, considering death as a
competing risk and comparing groups by the Gray test. Confidence
intervals were estimated (95% CI) using the Simon and Lee method.
Logistic regression and Cox proportional hazard regression models were
done to examine and check for treatment results and the risk factors
affecting CR rate and time to event. All analyses were carried out in
SAS 8.02, methods for competing risks were applied using the macro
CIN created by the Department of Biostatistics of the St. Jude Children
Research Hospital, Memphis, TN.
Results
Study group and treatment response. The study included 62
patients: 43 males and 19 females with a median age of 70 years
(range, 53-83 years). According to the French-American-British
classification, diagnosis was RAEB for 39 patients (62.90%),
RAEBT for 19 patients (30.65%), and CMML for 4 patients
(6.45%). Patient characteristics are shown in Table 1. The IPSS
was Intermediate-2 for 42 patients and High for 20 patients. A
VPA concentration between 45 and 55 μg/mL was reached in a
median of 7 days (range, 2-28 days), whereas the median VPA
concentration during treatment was 56.6 μg/mL (range, 16.0-
285 μg/mL).
A median of six 5-AZA cycles (range, 0-8) were administered.
Three patients died before treatment started, 41 patients com-
pleted four cycles, whereas 26 patients completed eight cycles
and were evaluable for treatment response (Table 2). The me-
dian duration for each of the first four cycles was 39 days
(range, 31-103 days), whereas the last four cycles were admin-
istered every 37.5 days (median range, 30-82 days).
The CR/PR rate in patients which completed eight cycles was
30.7%, and the disease was stable in 38.5% of patients (Table 2).
There were four patients who achieved HI. The median time to
achieve CR was 5.4 months (range, 2.0-9.8 months). ATRA was
Table 2. Treatment response
After four
cycles (n = 41)
After eight
cycles (n = 26)
Hematologic improvement 12 (29.3%) 4 (15.4%)
Stable disease 20 (48.9%) 10 (38.5%)
Failure 4 (9.7%) 4 (15.4%)
CR 1 (2.4%) 3 (11.5%)
PR 4 (9.7%) 5 (19.2%)
Table 3. Organ toxicity (National Cancer Institute-
Common Toxicity Criteria scale)
Grade 1-2
(events)
Grade 3-4
(events)
Allergy 56 1
Cardiovascular 57 1
Coagulation 19 0
Cutaneous rash 48 0
Gastrointestinal (colitis) 25 2
Gastrointestinal (diarrhea) 22 0
Gastrointestinal (stomatitis) 20 0
Bleeding 13 3
Liver bilirubin 24 0
Liver sGPT 19 0
Neurology (pain) 18 0
Neurology (sensory) 19 1
Neurology (motor) 19 0
Ocular (conjunctivitis) 19 1
Lung (dyspnea) 20 5
Kidney (creatinine) 19 0
Hematology (anemia) 39 14
Hematology
(thrombocytopenia)
28 35
Hematology (neutropenia) 20 48
NOTE: Three hundred and thirty-one cycles of therapy.
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added in 11 patients on cycle 5, without significant clinical ben-
efit (data not shown). Of 36 patients who did not complete eight
cycles, 3 died before treatment started, 2 refused treatment, 12
discontinued treatment for toxicity, 13 for disease progression,
and 6 for medical decision.
Transfusion needs decreased from amedian of 3 RBCunits/mo
(range, 0-8) to 1.5/mo (range, 0-10) after four cycles, and 0/mo
after treatment completion (range, 0-7; P = 0.165). The disease
progressed in 20 patients, with 21% cumulative incidence of pro-
gression at 10 months (95% CI, 20.4-21.6 months). The median
follow-up was 12 months (range, 0.7-21.0). On an intent to
treat basis, 32 patients (58.7%; 95% CI, 51.3-67.1) were
alive at 12 months and 3 patients died before treatment
started, whereas 27 died due to disease progression (9 patients,
33.4%), infections (11 patients, 40.7%), hemorrhage (2 patients,
7.4%), cardiovascular complications (3 patients, 11%), and
other causes (2 patients, 7.4%).
Toxicity. Patients were evaluable for toxicity for a total of
331 treatment cycles. The number of grade 3 to 4 toxicities dur-
ing therapy is shown in Table 3 (n = 30 patients). The most
frequent toxicity was hematological with 97 events (anemia,
14; thrombocytopenia, 35; and neutropenia, 48), resulting in
four grade 1 to 2 and four grade 3 to 4 fever of unknown origin
(FUO).
The most frequent events related to VPA was grade 1 to 2
neurotoxicity (n = 6 patients), mainly somnolence and confu-
sion, followed by fatigue, which were transient and reversible.
Severe toxicity leading to treatment discontinuation was ob-
served in 12 patients (7 due to infectious, 3 to cardiovascular
complications, and 2 for neurologic toxicity).
Prognostic factors for outcome. We were interested in the
prognostic factors playing a significant role for overall survival.
The IPSS score (High versus Intermediate-2) maintained its
prognostic relevance. Transformation into AML or progression
occurred in 20 patients and were significantly more frequent
in patients with a high IPSS when compared to those with In-
termediate-2 IPSS scores (at 10 months, 45.0% versus 10.2%;
P = 0.006). A high IPSS score was also a significant negative
prognostic factor for survival (median survival, 8.9 versus
18.7 months; HR, 2.69; 95% CI, 1.23-5.87; P = 0.013; Fig. 1).
At univariate analysis, further factors associated with survival
were VPA serum concentration (≥50 μg/mL versus <50 μg/mL;
HR, 0.35; 95% CI, 0.16-0.77), median survival 18.7 versus 10
months (P = 0.009; Fig. 2), hemoglobin (as a continuous
variable; HR, 0.67; 95% CI, 0.50-0.89; P = 0.006) and plate-
let counts (as a continuous variable; HR, 0.99; 95% CI,
0.981-0.999; P = 0.024). In this line, VPA serum concentra-
tion also predicted the achievement of CR or PR (as a con-
tinuous variable; median, 66 versus 53 μg/mL; P = 0.04).
Older age as a continuous variable had a trend towards
worse survival (HR, 1.046; 95% CI, 0.994-1.101; P = 0.08),
whereas karyotype and addition of ATRA (11 patients) did
not influence response or survival.
The multivariate analysis confirmed the prognostic role of
IPSS score (High versus Intermediate-2; HR, 2.778; 95% CI,
1.054-7.316; P = 0.039), of hemoglobin concentration (HR,
0.678; 95% CI, 0.46.2-0.996; P = 0.047), and VPA serum con-
centration (HR, 1.001; 95% CI, 1.000-1.002; P = 0.007) consid-
ered as continuous variables.
Genomic polymorphisms. Analysis of the polymorphisms
important for metabolism of the drugs used in the trial
showed that a variant of cytochrome P450 (CYP450),
CYP2C19*2, influenced the VPA dose necessary to achieve
the target VPA concentration of 50 μg/mL on day 1 of AZA
treatment. Carriers of this single nucleotide polymorphism
required higher VPA doses compared with wild-type subjects
(median, 609 versus 600 mg; range, 600-1,400 versus 600-
1,000; P = 0.0021). Other enzymatic polymorphisms, includ-
ing CYP3A4-A290G, GSTP1-Ile105Val, and cytidine deaminase
(CDA-92A>G, CDA-451C>T, and -897C>A) did not play a
role as predictors of toxicity or response.
Discussion
In this multicenter study, we show that epigenetic therapy,
combining the DNMTi5-ZA with the HDACi VPA, is active
and associated with a high response rate in patients with
MDS and unfavorable prognosis.
Azacytidine, as a single agent, was shown to be effective in
patients with MDS (21, 22). These data have been confirmed
in a phase III, multicenter, randomized, prospective trial which
included 358 patients with MDS, demonstrating the superiority
of azacytidine over three conventional care regimens (median
Fig. 1. Survival by the IPSS score. MDS patients with an Intermediate-2
IPSS score (continuous line) had a significantly better progression-free
(A) and overall (B) survival (log rank = 0.006 and 0.013, respectively), than
patients with a high IPSS (broken line).
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overall survival, 24.4 versus 15 months; ref. 23). The synergistic
activity of azacytidine and the HDACi VPA, in an attempt to
restore sensitivity to the differentiating effect of ATRA, was test-
ed in 49 refractory/relapsed or de novo AML and 4 MDS patients
(24). A 42% overall response rate was observed, with most re-
sponses at the VPA dose of 50 mg/kg, after a median of one
course. Blum et al. obtained a 44% response with decitabine
alone or combined with VPA in 25 patients with AML (12).
VPA at 15 to 25 mg/kg did not improve the response to decita-
bine, but induced dose-limiting encephalopathy at plasma le-
vels within or just above 120 μg/mL, the upper limit of the
therapeutic range (12). The German MDS study group treated
25 poor-risk MDS and AML patients with 5-AZA at an increased
dose of 100 mg/m2/d for 5 days combined to VPA, to achieve
serum levels of 80 to 110 μg/mL. The response rate was 33%
and the median survival was 8 months (13). Myelosuppression
seemed to be more severe than with 5-AZA alone and most
patients had transient central nervous system side effects lead-
ing to a dose reduction or transient discontinuation. Similar
remission rates were reported in AML patients treated using
the 5-AZA/VPA combination (25, 26).
In our prognostically unfavorable, elderly, higher risk MDS
patients (also including three patients who died before treat-
ment started), the median overall survival on an intent to treat
basis was 14.4 months. Toxicity leading to treatment discontin-
uation was observed in 12 patients. The survival rate was infe-
rior to that reported by the AZA-001 international trial (23),
and is more similar to data reported by the Cancer and Leuke-
mia Group B on high-risk MDS/WHO-AML (21, 22).
A significantly superior survival (18.7 months) was observed
for patients reaching a plasma VPA concentration of >50 μg/mL.
This indicates that the addition of the HDACi VPA to azacyti-
dine improves the response. Similarly, in the M.D. Anderson
series (24), significantly higher response rates were observed
in patients reaching higher VPA concentration, but there was
no association between the dose administered and response.
This points out that specific targeting of VPA plasma levels
should be used instead of doses based on weight, and that
factors influencing plasma VPA concentration may play a sig-
nificant role.
At present, we do not have any valuable parameter, either
disease-associated or patient-associated, predictive of response
to DNMTi or to the combination of DNMTi and HDACi.
None of the methylation studies done thus far during hypo-
methylating treatment have found reliable predictors of re-
sponse (12, 24). Soriano et al. found a significant decrease
in global methylation by day 7 of treatment, but the degree
of hypomethylation did not differ between responders and
nonresponders (24). This may be due to the presence of
genome-wide hypomethylation concomitant with specific
tumor suppressor gene hypermethylation in MDS and AML.
Prospective biological and clinical studies are warranted to
define a patient-tailored approach. We studied the pharmaco-
genomic profile of patients, and in particular, the genomic
polymorphisms of GSTP1, of the CYP450 enzyme, which
has been shown to be important for the hepatic metabolism
of psychotropic drugs, and of cytidine deaminase, which is
important for the inactivation of azacytidine. The polymorph-
isms CYP3A4-A290G and GSTP1-Ile105Val did not play a role
as predictors of toxicity or response. Similarly, no effects were
shown for the cytidine deaminase promoter region poly-
morphisms CDA-92A>G, CDA-451C>T, and -897C>A, which
have been shown to significantly decrease CDA activity, espe-
cially when combined with haplotype 3 (19).
On the other hand, carriers of the CYP2C19*2 variants of
CYP450 (slow metabolizers; ref. 27) required higher VPA doses
to achieve the target VPA concentration of 50 μg/mL on day 1
of AZA treatment, which had a significant prognostic role for
survival. The definition of this enzymatic polymorphism may
help to identify patients with a favorable profile and define a
patient-tailored approach.
The addition of the differentiating agent ATRA to azacytidine
and VPA in 11 patients did not improve the response rate, in-
dicating that demethylation may not be able to restore im-
paired differentiation in MDS. Larger patient numbers may be
required to answer this issue.
In conclusion, our study shows good efficacy and tolerability
of the combination therapy in higher risk MDS, but many is-
sues are still open. In fact, there is no consensus on which
schedule and dose of both drugs should be used, nor do we
possess biomarkers to predict prognosis. It is equally possible
that aside from epigenetic effects, DNMTi and HDACi exert
their activity through epigenetically independent induction of
DNA damage, requiring better determination of the drug targets
in patients with MDS.
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Fig. 2. The plasma VPA concentration significantly affects overall survival.
The achievement of a VPA concentration of >50 μg/mL (continuous line)
on the first day of 5-AZA treatment (median, on day 12; range, 3-69)
was associated with superior overall survival when compared with lower
VPA concentrations (broken line, log rank = 0.007).
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